Lawmakers dive into the structural market failures behind chronic drug shortages — and why fragile global supply chains make lifesaving medicines harder to secure.
Clinical trials are being halted, early-career researchers are losing funding, and rural institutions face growing disparities in access to NIH support. The future of U.S. biomedical research—and its global leadership—is under scrutiny.
Cuts, Conflicts, and Controversies: Medicaid and NIH funding are front and center as the Senate finalizes the One Big Beautiful Bill Act
From staffing shortages to stalled sanitation projects, lawmakers sounded the alarm on systemic cracks in IHS operations—and signaled where future dollars must go.
Only 3 drugs switched to OTC in 3 years. Lawmakers push for answers on sunscreen, shortages, and workforce cuts.
The "Megabill" reconciliation package could reshape the safety net—and fracture the Senate caucus
Senators challenge Commissioner Makary on staff cuts, drug approvals, rare diseases research, and more
Senate HSGAC members receive testimony accusing federal agencies of suppressing critical vaccine safety data.
3,200+ grants paused, rural programs cut, and AHA reorganization under fire
Medicaid, PBMs, and Market Shakeups in the Crosshairs
Lawmakers from both chambers pressed Secretary Kennedy over sweeping staff reductions, vaccine messaging, and slashed funding to NIH, CDC, and maternal health—raising urgent questions about America's healthcare future.
GOP pushes deep cuts after an Energy & Commerce marathon markup. Here’s what made it in — and what’s at stake.
